SKP2 and lung cancer: This phenomenon that structure-based inhibitor of Skp2 was more efficient than non-structure-based compounds, was also observed in lung cancer cell line H520, H69, H196 and primary mouse small cell lung cancer (SCLC) cell, in which IC50 value of Skp2 inhibitor SKPin C1 was lower than MLN4924 and Flavokawain A (Zhao et al., 2020).